Mersana Therapeutics have expanded their ongoing collaboration with Takeda Pharmaceutical to create novel Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets.
Mersana is eligible to receive additional upfront and milestone payments potentially totaling over $300 million under the expanded collaboration subject to future success of the programs.
|Searching for more deal information? Current Partnering offers the following options:
The partners’ collaboration was announced in April 2014, and since then, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana’s Fleximer-ADC technology.
Takeda has already exercised an option to license commercial rights for the first drug candidate developed under this collaboration, which was announced in October 2014.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends